Jun 17 2011
Ischemix today announced positive top line data from a Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative cardiac ischemia-reperfusion injury. The trial achieved its primary endpoint of safety with CMX-2043 demonstrating a favorable safety profile at all doses, consistent with the Phase 1 data. Additionally, although the trial was not powered to show statistical differences in efficacy, CMX-2043 demonstrated positive trends in all secondary efficacy endpoints and achieved statistically significant benefits in a key endpoint measure of cardiac health. CMX-2043 is a cardio-protective drug candidate that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule. Ischemix intends to submit detailed results from the CMX-2043 Phase 2a trial for presentation at an upcoming medical meeting.
“We believe that the Phase 2 safety and efficacy data for CMX-2043 are very promising. CMX-2043 represents a potential new approach to prevention of peri-operative ischemia-reperfusion injury, a field where previous drug candidates have not succeeded in clinical studies”
"We believe that the Phase 2 safety and efficacy data for CMX-2043 are very promising. CMX-2043 represents a potential new approach to prevention of peri-operative ischemia-reperfusion injury, a field where previous drug candidates have not succeeded in clinical studies," commented Duffy DuFresne, Chief Executive Officer of Ischemix.